Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Official title

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

Overview

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Detailed description

This is a Phase 1/2 study of Rina-S; also known as GEN1184, formerly known as PRO1184, a folate receptor alpha (FRα) targeted antibody-drug conjugate, to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Rina-S in participants with selected locally advanced and/or metastatic solid tumors, including epithelial ovarian cancer, endometrial cancer, breast cancer, non-small cell lung cancer, and mesothelioma.

The study consists of multiple parts:

Part A: monotherapy cohorts

Part B: tumor-specific monotherapy dose-expansion cohorts

Part C: platinum-resistant ovarian cancer (PROC) monotherapy cohort

Part D: combination therapy cohorts

Part E: a monotherapy PROC cohort

Parts F and G: a monotherapy endometrial cancer (EC) cohort

Part H: a monotherapy PROC cohort

Part I: platinum-sensitive ovarian cancer (PSOC) cohort

Part J: a monotherapy PROC cohort

Part K: a monotherapy high-grade ovarian cancer cohort

Participants will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, pregnancy, or death.

Interventions

• Drug Rina-S
  Intravenous infusion of Rina-S
• Drug Carboplatin
  Carboplatin intravenous infusion
• Drug Bevacizumab
  Bevacizumab intravenous infusion
• Drug Pembrolizumab
  Pembrolizumab intravenous infusion

Primary outcome measures

• Parts A, B, and D - Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability] [Time frame: Through end of treatment, up to approximately 1 year.]
• Parts A, and D - Dose Limiting Toxicity (DLT) [Time frame: At the end of Cycle 1 (each cycle is 21 days)]
• Parts C, E, F, G, H, I, and J- Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR, Parts C and F) or Investigator (Part E, G, I, and J) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [Time frame: Through end of treatment, up to approximately 1 year.]
• Part K (US Participants Only) - Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Findings by Holter [Time frame: Cycles 1 to 3 (each cycle is 21 days)]

Secondary outcome measures (12)

• Parts A, B, and D - Best Overall Response (BOR) [Time frame: Up to approximately 1 year.]
• Parts A, B, D, and E - ORR [Time frame: Up to approximately 1 year.]
• Parts A, B, and D - Disease Control Rate (DCR) [Time frame: Up to approximately 1 year.]
• Parts A, B, C, D, E, F, G, H, I, and J - Progression-Free Survival (PFS) [Time frame: Through end of treatment, up to approximately 1 year.]
• Parts C, E, F, G, H, I and J - Overall survival (OS) [Time frame: Up to approximately 2 years.]
• Parts A, B, C, D, E, F, H, I and J - Duration of Objective Response (DOR) [Time frame: From date of enrollment until the date of first documented disease progression or date of study withdrawal, whichever came first, assessed up to 12 months.]
• Parts A, B, D, and E - Peak Plasma Concentration (Cmax) for Rina-S [Time frame: Through end of treatment, up to approximately 1 year.]
• Parts A, B, D, and E - Area Under the Plasma Concentration Versus Time Curve (AUC) for Rina-S [Time frame: Through end of treatment, up to approximately 1 year.]
• Parts A, B, D, and E -Time to Reach Cmax (Tmax) for Rina-S [Time frame: Through end of treatment, up to approximately 1 year]
• Parts A, B, D, and E - Trough Concentrations (Ctrough) for Rina-S [Time frame: Through end of treatment, up to approximately 1 year]
• Parts A, B, D, and E- Apparent Terminal Half-life (t1/2) for Rina-S [Time frame: Through end of treatment, up to approximately 1 year]
• Parts C, D, E, H and J - CA-125 Response Determined Using the Gynecologic Cancer Intergroup (GCIG) Criteria [Time frame: Through end of treatment, up to approximately 1 year]

Eligibility criteria

Inclusion criteria

Part A and B:

• Histologically or cytologically confirmed metastatic or unresectable solid malignancy including ovarian cancer (must have epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, HER2-negative and triple-negative) (Part A), mesothelioma or cervical cancer (Part B).
• Previously received therapies known to confer clinical benefit.
• Measurable disease per RECIST v1.1 for all tumor types other than pleural mesothelioma which will use mRECIST v1.1 at baseline.

Part C, E, and H:

Participants must have histologically or cytologically confirmed metastatic or unresectable epithelial ovarian cancer as specified below.

• High grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (excluding endometrioid, clear cell carcinomas, mucinous, low grade, and those with a sarcomatous or neuroendocrine element)
• Participants must have received up to 3 prior lines of therapy. Participants may have had up to to 4 prior lines of therapy are allowed if MIRV is locally approved and was used as the last line of therapy. Participants must have progressed radiographically on or after their most recent line of therapy.
• Participants must have platinum-resistant ovarian cancer.
• Participants must have received prior bevacizumab or approved biosimilar.
• Participants with known or suspected deleterious germline or somatic BRCA mutations (as determined by Food and Drug Administration \[FDA\]-approved test in a Clinical Laboratory Improvement Amendments \[CLIA\]-certified laboratory; or locally approved equivalent) and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment.
• Measurable disease per the RECIST v1.1 at baseline.

Part D:

Cohort D1:

• Participants must have platinum-sensitive ovarian cancer.
• Participants must have received 1 to 3 prior lines of therapy.

Cohort D2:

• Participants must have primary platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer.
• Participants with primary platinum-refractory ovarian cancer must have received ≤2 prior lines of therapy. Primary platinum-refractory ovarian cancer is defined as a lack of response or by progression within 91 days after completing front-line platinum containing therapy.
• Participants must have received 1 to 3 prior lines of therapy for platinum-resistant ovarian cancer (PROC), and up to 4 prior lines of therapy for platinum-sensitive ovarian cancer (PSOC). Prior treatments may have included bevacizumab, PARP inhibitor, and MIRV.

• Participants with PSOC must have disease progression on or after maintenance treatment, or at least 6 months (>183 days) or more from the last dose of platinum-based therapy.

Cohort D3:

• Endometrial cancer (any subtype excluding sarcoma).

Cohort D4:

• Primary advanced or recurrent endometrial cancer (any subtype excluding sarcoma and neuroendocrine tumors).

Part F and G:

• Participants must have histologically or cytologically confirmed EC.
• Recurrent progressive EC (any subtype excluding neuroendocrine tumors, carcinosarcoma, or endometrial sarcoma) following prior therapy.
• Participants must have received 1 to 3 prior lines of therapy, and must have progressed radiographically on or after their most recent line of therapy:
• Participants must have received prior platinum-based chemotherapy and a programmed death-ligand 1 (PD-\[L\])1 inhibitor.
• Participants who progress >12 months after completion of prior adjuvant or neoadjuvant platinum-based chemotherapy must receive 1 additional cytotoxic systemic treatment prior to enrollment in this study.
• Hormonal therapy alone (i.e., without chemotherapy) will not be counted as a separate line of therapy.
• Measurable disease per the RECIST Version 1.1 at baseline.

Part I:

• Participants must have histologically or cytologically confirmed high grade serous or endometrioid epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer (excluding clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies or low grade/borderline ovarian tumors).
• Participants must have platinum sensitive ovarian cancer.
• Measurable disease per the RECIST Version 1.1 at baseline.

Part J:

• Participants must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element.
• Measurable disease per the RECIST Version 1.1 at baseline.

Part K:

• Participants must have histologically or cytologically confirmed metastatic or unresectable ovarian cancer (must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element).
• Participants must have primary platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer.
• Measurable disease per the RECIST Version 1.1 at baseline.

Exclusion criteria

• History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids within the past 2 years, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
• Prior therapy with a topoisomerase 1 inhibitor-based antibody drug conjugate.

Note: Other protocol-defined inclusion/exclusion may apply.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 37 centers

• USOR HonorHealth — Phoenix
• USOR Arizona Oncology Associates — Tucson
• University of California Los Angeles Medical Center — Los Angeles
• University of California, San Diego; Moores Cancer Center — San Diego
• USOR Sansum Clinic — Santa Barbara
• Providence Medical Foundation — Santa Rosa
• USOR Florida Cancer Specialists South — Fort Myers
• USOR Florida Cancer Specialists North — St. Petersburg
• … and 29 more centers

China · 20 centers

• Cancer hospital, Chinese Academy of Medical Sciences — Beijing
• Chongqing University Cancer Hospital — Chongqing
• Hunan Cancer Hospital - Phase 1 — Changsha
• Hunan Cancer Hospital - Thoracic Medicine Dept II — Changsha
• Jiangxi Maternal and Child Health Hospital — Nanchang
• Jilin Cancer Hospital — Changchun
• Obstetrics & Gynecology Hospital of Fudan University — Chengdu
• Fudan University Shanghai Cancer Center - Gynecologic Oncology — Shanghai
• … and 12 more centers

Japan · 9 centers

• Fukushima Medical University Hospital — Fukushima
• Gunma Prefectural Cancer Center — Ōta
• Sapporo Medical University Hospital — Sapporo
• Hyogo Cancer Center — Akashi
• Saitama Medical University-International Medical Center — Hidaka
• Shizuoka Cancer Center — Nagaizumi-chō
• Cancer Institute Hospital of JFCR — Koto
• Keio University Hospital — Shinjuku-ku
• … and 1 more center

Identifiers

NCT: NCT05579366 · GCT1184-01 · CTR20230813 · jRCT2051250094 · PRO1184-001

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)
• NMPA/CDE CTR20230813 (chinadrugtrials.org.cn platform)

View this study on ClinicalTrials.gov ↗